AGMB Financial Snapshot

The global Crohn's disease therapeutics market is projected to grow at a CAGR of 2.7% from 2024 to 2030, according to Grandview Research. The company currently has cash and cash equivalents totaling €116.5 million as of December 31, 2025. AGMB shares closed Tuesday's trade at $11.94, up 0.84%.